Background: Bronchiolitis obliterans syndrome (BOS) is the major limitation to long-term survival following lung transplantation and strategies to reduce its incidence have remained elusive. Macrolides may stabilize lung function in patients with established BOS. Their role, however, in prevention of BOS remains unexamined
Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obli...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients ...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: This review ...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Introduction Azithromycin stabilises and improves lung function forced expiratory volume in one seco...
BACKGROUND: Azithromycin may reverse or halt the decline of pulmonary function (FEV(1)) in bronchiol...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival...
<div><p>Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term ...
Rationale: Bronchiolitis obliterans syndrome (BOS) is the primary limiting factor for long-term surv...
Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obli...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
Bronchiolitis obliterans syndrome (BOS) is the leading cause of death in lung transplant recipients ...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: This review ...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Introduction Azithromycin stabilises and improves lung function forced expiratory volume in one seco...
BACKGROUND: Azithromycin may reverse or halt the decline of pulmonary function (FEV(1)) in bronchiol...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the leading cause of morbidity/mortality in l...
Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transpl...
Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival...
<div><p>Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term ...
Rationale: Bronchiolitis obliterans syndrome (BOS) is the primary limiting factor for long-term surv...
Prophylactic azithromycin treatment has been demonstrated to improve freedom from bronchiolitis obli...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...